Clinical Trial

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 7 locations 2026-07-03
Trial Details
NCT Number NCT07558733
Lead Sponsor Faeth Therapeutics
Conditions HR+ HER2- Breast Cancer
Enrollment 32 participants
Start Date 2026-04-22
Primary Completion 2029-05 (estimated)
Study Completion 2033-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-02